Sugi Predict

Sugi Predict / Compounds / SCHEMBL555322

SCHEMBL555322

SCHEMBL555322

NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c([N+](=O)[O-])c1

nearest known ligand 0.72

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ BCL2L1 Q07817 19/20 0.72
▸ BCL2 P10415 14/20 0.68
▸ BCL2L2 Q92843 6/20 0.68
▸ MCL1 Q07820 1/20 0.62
▸ ALB P02768 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29482082 1.00 BCL2L1 (0.72) BCL2L1BCL2BCL2L2MCL1ALB
SCHEMBL3819345 1.00 BCL2L1 (0.72) BCL2L1BCL2BCL2L2MCL1ALB
SCHEMBL555323 1.00 BCL2L1 (0.72) BCL2L1BCL2BCL2L2MCL1ALB
SCHEMBL25422833 0.97 BCL2L1 (0.68) BCL2L1BCL2BCL2L2MCL1ALB
SCHEMBL25422835 0.97 BCL2L1 (0.68) BCL2L1BCL2BCL2L2MCL1ALB
SCHEMBL3819283 0.93 BCL2L1 (0.70) BCL2L1BCL2BCL2L2MCL1ALB
SCHEMBL31570886 0.93 BCL2L1 (0.70) BCL2L1BCL2BCL2L2MCL1ALB
SCHEMBL4747130 0.92 BCL2L1 (0.69) BCL2L1BCL2BCL2L2MCL1ALB
SCHEMBL3822342 0.92 BCL2L1 (0.69) BCL2L1BCL2BCL2L2MCL1ALB
SCHEMBL3823004 0.92 BCL2L1 (0.69) BCL2L1BCL2BCL2L2MCL1ALB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE50643-E1 Benzamide compounds RECURIUM IP HOLDINGS, LLC (US) 2025-10-21 — — US disclosed
EP-4556469-A1 BENZAMIDE COMPOUNDS Recurium IP Holdings, LLC (US) 2025-05-21 — — EP disclosed
EP-3740487-B1 BENZAMIDE COMPOUNDS AS BCI INHIBITORS FOR THE TREATMENT OF HIV RECURIUM IP HOLDINGS LLC (US) 2025-01-08 — — EP disclosed
US-20240180899-A1 BENZAMIDE COMPOUNDS RECURIUM IP HOLDINGS, LLC 2024-06-06 — — US disclosed
CN-118084904-A Benzamide compounds 里科瑞尔姆IP控股有限责任公司 2024-05-28 — — CN disclosed
CN-118084905-A Benzamide compounds 里科瑞尔姆IP控股有限责任公司 2024-05-28 — — CN disclosed
CN-111801327-B Benzamide compounds 里科瑞尔姆IP控股有限责任公司 2024-02-09 — — CN disclosed
US-11813260-B1 Benzamide compounds RECURIUM IP HOLDINGS, LLC (US) 2023-11-14 — — US disclosed
US-11813259-B2 Benzamide compounds RECURIUM IP HOLDINGS, LLC (US) 2023-11-14 — — US disclosed
US-11813260-B1 Benzamide compounds RECURIUM IP HOLDINGS, LLC (US) 2023-11-14 — — US disclosed
US-20070072860-A1 N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide ABBOTT LABORATORIES 2007-03-29 — — US disclosed
US-20070015787-A1 Apoptosis promoters ABBVIE INC. 2007-01-18 — — US disclosed
US-20060258657-A1 Apoptosis promoters ABBVIE INC. 2006-11-16 — — US disclosed
US-20060128706-A1 Apoptosis promoters ABBVIE INC. 2006-06-15 — — US disclosed
EP-1318978-B1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2006-02-08 — — EP disclosed
US-20050159427-A1 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES 2005-07-21 — — US disclosed
US-20040192681-A1 N-acylsulfonamide apoptosis promoters ABBVIE INC. 2004-09-30 — — US disclosed
US-6720338-B2 BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL ABBOTT LABORATORIES 2004-04-13 — — US disclosed
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters ABBVIE INC. 2002-07-04 — — US disclosed
US-20020055631-A1 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES 2002-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 BCL2L1 5/4885BCL2 3/4885BCL2L2 19/4885
US-20060128706-A1 Apoptosis promoters BAX, BCL2, API5 BCL2L1 10/4885BCL2 2/4885BCL2L2 16/4885
US-11813259-B2 Benzamide compounds MKI67, TMBIM6, HDAC1 BCL2L1 86/4885BCL2 69/4885BCL2L2 253/4885
US-11813260-B1 Benzamide compounds MKI67, TMBIM6, HDAC1 BCL2L1 86/4885BCL2 69/4885BCL2L2 253/4885
US-20020055631-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 BCL2L1 4/4885BCL2 3/4885BCL2L2 18/4885
US-20040192681-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 BCL2L1 5/4885BCL2 3/4885BCL2L2 19/4885
US-20070015787-A1 Apoptosis promoters BAX, BCL2, API5 BCL2L1 10/4885BCL2 2/4885BCL2L2 16/4885
US-20060258657-A1 Apoptosis promoters BAX, BCL2, API5 BCL2L1 10/4885BCL2 2/4885BCL2L2 16/4885
US-20050159427-A1 N-acylsulfonamide apoptosis promoters BAX, API5, CCAR2 BCL2L1 20/4885BCL2 4/4885BCL2L2 33/4885
US-20240180899-A1 BENZAMIDE COMPOUNDS MKI67, TMBIM6, HDAC1 BCL2L1 86/4885BCL2 69/4885BCL2L2 253/4885
US-20070072860-A1 N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide BCL2A1, BAX, BCL2L1 BCL2L1 3/4885BCL2 4/4885BCL2L2 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.